Roth Capital analyst Joe Reagor lowered the firm’s price target on IperionX (IPX) to $71 from $74 and keeps a Buy rating on the shares after its results for the first half of 2026. The firm had previously anticipated the company would begin to generate revenue during this period but it now anticipates an initial ramp in revenue in the second half of 2026, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPX:
- IperionX Files December 2025 Half‑Year Results, Revealing Wider Interim Loss
- IperionX CEO says entering 2026 in ‘strong position’
- IperionX: Transition to Commercial-Scale Titanium Production Underpins Capacity-Driven Growth and Buy Rating
- IperionX receives prototype order for U.S. Army heavy ground combat system
- Why Is IperionX Stock (IPX) Rising?